Acute myocardial infarction following paclitaxel administration for ovarian carcinoma

Clinical Oncology

Volumn 9, Issue 2, 1997, Pages 124-126

  Laher, S ^a   Karp, S J ^a  

^a NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Myocardial infarction; Ovarian carcinoma; Paclitaxel

Indexed keywords

PACLITAXEL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0030903701     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(05)80452-2     Document Type: Article

References (22)

1. Piccart MJ. News from the NCI Taxol Workshop. Eur Cancer News 1993;6:1-3.
2. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704-12.
3. Rowinsky EK, Eisenhauer EA, Chaudry V, et al. Clinical toxicities encountered with paclitaxel. Semin Oncol 1993;20 (4 Suppl 3):1-15.
4. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst Monogr 1993;15:117-30.
5. Brouty-Boye D, Kolonias D, Lampidis TJ. Antiproliferative activity of taxol on human tumour and normal breast cells vs. effects on cardiac cells. Int J Cancer 1995;60:571-5.
6. Lampidis TJ, Colnias D, Savaraj N, et al. Cardiostimulatory and antiarrhythmic activity of tubulin-binding agents. Proc Natl Acad Sci USA 1992;89:1256-60.
7. Jekunen A, Heikkila P, Maiche A, et al. Paclitaxel-induced myocardial damage detected by electron microscopy [letter]. Lancet 1994;343:727-8.
8. Holmes FA, Walters RS, Theriault RL, et al. Phase 2 trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
9. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: A Phase I and pharmacologic study. J Clin Oncol 1991;9:1692-703.
10. Forastiere AA, Neuberg D, Taylor SG, et al. Phase 2 evaluation of taxol in advanced head and neck cancer: An ECOG trial. J Natl Cancer Inst Monogr 1993;15:181-4.
11. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced hormone-refractory carcinoma of the prostate. Cancer 1993; 72:2457-60.
12. Brown T, Tangen C, Fleming T, et al. A Phase 2 trial of taxol and G-CSF in patients with adenocarcinoma of the pancreas. Proc ASCO 1993;12:abstr. 592.
13. Chang AY, Kim K, Glick J, et al. Phase 2 study of taxol, merbarone and piroxantrone in Stage IV non-small cell lung cancer: The ECOG results. J Natl Cancer Inst 1993;85:388-94.
14. Schiller JH, Storer B, Tutsch K, et al. A Phase I trial of 3-hour infusions of paclitaxel with or without G-CSF. Semin Oncol 1994;21(5 Suppl 8):9-14.
15. Klastersky J, Sculier JP. Dose-finding study of paclitaxel plus cisplatin in patients with non-small cell lung cancer. Semin Oncology 1994;21(5 Suppl 8):39-44.
16. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour infusion on a weekly basis. J Clin Oncol 1994;12:1458-67.
17. Sulkes A, Beller U, Petretz T, et al. Taxol: Initial Israeli experience with a novel anti-cancer agent. Isr J Med Sci 1994;30:70-8.
18. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase 2 study of paclitaxel in patients with extensive disease small-cell lung cancer: An ECOG study. J Clin Oncol 1995;13:1430-5.
19. Younes A, Sarris A, Melnyk A, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995;13:583-7.
20. Johnson DH, Chang AY, Ettinger DS. Taxol in the treatment of lung cancer: The ECOG experience. Ann Oncol 1994;5(Suppl6):545-50.
21. Hentschel P, Vlay S, Madajewicz S, et al. Ischaemia associated with taxol chemotherapy. Proc ASCO 1995;14:abstr. 1588.
22. Kawauchi R, Bonomi P, Faber LP, et al. Phase I trial of escalating doses of taxol combined with cisplatin, carboplatin, VP-16 and simultaneous thoracic radiation in Stage III non-small cell lung cancer. Proc ASCO 1995;14:abstr. 1193.